search
Back to results

A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

Primary Purpose

Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Metformin
Sitagliptin
Acarbose
Repaglinide
Glimepiride
Gliclazide
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Has Type 2 Diabetes Mellitus;
  • Agrees to use an effective method of contraception or must not otherwise be at risk of becoming pregnant (female participants).

Exclusion Criteria:

  • Has a history of type 1 diabetes mellitus or a history of ketoacidosis;
  • Has been treated with insulin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a Glucagon-like peptide-1 (GLP-1) mimetic or analogue before;
  • Is on a weight loss program (not in maintenance phase), has started a weight loss medication, or has undergone bariatric surgery within 12 months;
  • Has undergone a surgical procedure within 4 weeks;
  • Has had new or worsening signs or symptoms of coronary heart disease or congestive heart failure within past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder;
  • Has a medical history of active liver disease, including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease;
  • Has poorly controlled hypertension;
  • Has severe peripheral vascular disease;
  • Has human immunodeficiency virus (HIV);
  • Has had a clinically important hematological disorder;
  • Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking;
  • Has a history of intolerance or hypersensitivity or any contraindication to study medications (including sitagliptin, metformin, glimepiride, repaglinide, acarbose or gliclazide) based upon the Chinese label;
  • Is on or likely to require treatment with ≥2 consecutive weeks or repeated courses of pharmacologic doses of corticosteroids (other than inhaled, nasal, or topical corticosteroids);
  • Is pregnant or breast feeding or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug (female participants).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Experimental

    Experimental

    Experimental

    Arm Label

    Metformin + Sitagliptin + Glimepiride

    Metformin + Sitagliptin + Repaglinide

    Metformin + Sitagliptin + Acarbose

    Metformin + Sitagliptin + Gliclazide

    Arm Description

    During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).

    Outcomes

    Primary Outcome Measures

    Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)
    HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction.

    Secondary Outcome Measures

    Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)
    Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used.
    Percentage of Participants With Hypoglycemia Events (Phase 2)
    Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported.
    Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)
    The percentage of participants with a GI AE of "nausea" was reported.
    Percentage of Participants With a GI AE of Vomiting (Phase 2)
    The percentage of participants with a GI AE of "vomiting" was reported.
    Percentage of Participants With a GI AE of Diarrhea (Phase 2)
    The percentage of participants with a GI AE of "diarrhea" was reported.
    Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)
    The percentage of participants with a GI AE of "abdominal pain" was reported.

    Full Information

    First Posted
    October 16, 2012
    Last Updated
    July 23, 2018
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01709305
    Brief Title
    A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)
    Official Title
    A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes Mellitus
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    November 8, 2012 (Actual)
    Primary Completion Date
    April 17, 2015 (Actual)
    Study Completion Date
    April 17, 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    To assess the effect of adding acarbose or repaglinide or gliclazide to sitagliptin plus metformin, compared to adding glimepiride, on glycemic improvements in Type 2 Diabetes Mellitus (T2DM) participants who require the addition of a third oral anti-hyperglycemic agent (OAHA) according to China Guideline for Type 2 Diabetes. The three co-primary hypotheses are that after 24 weeks of treatment in phase 2, the mean change from baseline in hemoglobin A1c (A1c) in participants receiving either (1)acarbose or (2)repaglinide or (3)gliclazide added to sitagliptin and metformin combination is non-inferior to that of participants receiving glimepiride added to sitagliptin and metformin combination. The study would be declared successful if at least one of the three primary hypotheses was met.
    Detailed Description
    Participants coming on study will be stabilized to a standardized metformin dose: this may take about 10 weeks, and then combination therapy with metformin + sitagliptin will begin during Phase 1 (Week 0 through Week 20). If a participant has already been on a stabilized metformin dose, they will start immediately on combination therapy with metformin + sitagliptin for 20 weeks (Phase 1). In Phase 2, participants who have failed to achieve adequate glycemic control (A1c ≥ 7% and ≤ 10% at Week 16 and fasting finger stick glucose ≥130 mg/dL and ≤280 mg/dL at Week 20) will be randomized to receive add-on therapy with glimepiride, repaglinide, acarbose, or gliclazide for 24 weeks (Week 20 through Week 44).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Type 2 Diabetes Mellitus

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    5570 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Metformin + Sitagliptin + Glimepiride
    Arm Type
    Active Comparator
    Arm Description
    During Phase 2, participants receive up to 6 mg glimepiride daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
    Arm Title
    Metformin + Sitagliptin + Repaglinide
    Arm Type
    Experimental
    Arm Description
    During Phase 2, participants receive up to 16 mg repaglinide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
    Arm Title
    Metformin + Sitagliptin + Acarbose
    Arm Type
    Experimental
    Arm Description
    During Phase 2, participants receive 50-100 mg acarbose three times daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
    Arm Title
    Metformin + Sitagliptin + Gliclazide
    Arm Type
    Experimental
    Arm Description
    During Phase 2, participants receive 30-120 mg gliclazide daily as an add-on to metformin + sitagliptin combination therapy for 24 weeks (Week 20 through Week 44).
    Intervention Type
    Drug
    Intervention Name(s)
    Metformin
    Other Intervention Name(s)
    Fortamet®, Glucophage®, Glucophage® XR, Glumetza®, Riomet®, Metgluco®, Glycoran®
    Intervention Description
    Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
    Intervention Type
    Drug
    Intervention Name(s)
    Sitagliptin
    Other Intervention Name(s)
    Januvia®, Tesavel®, Xelevia®, Ristaben®
    Intervention Description
    Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
    Intervention Type
    Drug
    Intervention Name(s)
    Acarbose
    Other Intervention Name(s)
    Precose®, Glucobay™
    Intervention Description
    Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
    Intervention Type
    Drug
    Intervention Name(s)
    Repaglinide
    Other Intervention Name(s)
    Prandin®, Fulaidi™
    Intervention Description
    Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
    Intervention Type
    Drug
    Intervention Name(s)
    Glimepiride
    Other Intervention Name(s)
    Amaryl®, Glimy
    Intervention Description
    Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
    Intervention Type
    Drug
    Intervention Name(s)
    Gliclazide
    Other Intervention Name(s)
    Diamicron MR™
    Intervention Description
    Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
    Primary Outcome Measure Information:
    Title
    Change From Phase 2 Baseline to Week 44 in Hemoglobin A1c (HbA1c) Levels (Phase 2)
    Description
    HbA1c is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Change from baseline reflects the Week 44 A1C minus baseline A1C. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used. Change from baseline was based on the constrained longitudinal data analysis (cLDA) model including all available measurements from baseline through the last visit. The terms in the cLDA model include treatment, time in weeks (categorical), regions, and treatment-by-time interaction.
    Time Frame
    Phase 2 Baseline (Week 20) and Week 44
    Secondary Outcome Measure Information:
    Title
    Change From Phase 2 Baseline to Week 44 in Participant Body Weight (Phase 2)
    Description
    Change from baseline in body weight in Phase 2 was reported. Change from baseline reflects the Week 44 body weight minus baseline body weight. Baseline is defined as Visit 6/Week 20. If this measurement was unavailable, the Week 16 value was used.
    Time Frame
    Phase 2 Baseline (Week 20), Week 44
    Title
    Percentage of Participants With Hypoglycemia Events (Phase 2)
    Description
    Hypoglycemia events represent epidsodes symptomatic of hypoglycemia (e.g., weakness, dizziness, shakiness, increased sweating, palpitations, or confusion) and/or finger stick glucose values of ≤70 mg/dL (3.9 mmol/L). The percentage of participants with hypoglycemia events was reported.
    Time Frame
    From Week 20 through Week 44
    Title
    Percentage of Participants With a Gastrointestinal (GI) AE of Nausea (Phase 2)
    Description
    The percentage of participants with a GI AE of "nausea" was reported.
    Time Frame
    From Week 20 through Week 44
    Title
    Percentage of Participants With a GI AE of Vomiting (Phase 2)
    Description
    The percentage of participants with a GI AE of "vomiting" was reported.
    Time Frame
    From Week 20 through Week 44
    Title
    Percentage of Participants With a GI AE of Diarrhea (Phase 2)
    Description
    The percentage of participants with a GI AE of "diarrhea" was reported.
    Time Frame
    From Week 20 through Week 44
    Title
    Percentage of Participants With a GI AE of Abdominal Pain (Phase 2)
    Description
    The percentage of participants with a GI AE of "abdominal pain" was reported.
    Time Frame
    From Week 20 through Week 44

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    75 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Has Type 2 Diabetes Mellitus; Agrees to use an effective method of contraception or must not otherwise be at risk of becoming pregnant (female participants). Exclusion Criteria: Has a history of type 1 diabetes mellitus or a history of ketoacidosis; Has been treated with insulin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, a Glucagon-like peptide-1 (GLP-1) mimetic or analogue before; Is on a weight loss program (not in maintenance phase), has started a weight loss medication, or has undergone bariatric surgery within 12 months; Has undergone a surgical procedure within 4 weeks; Has had new or worsening signs or symptoms of coronary heart disease or congestive heart failure within past 3 months, or has acute coronary syndrome, coronary artery intervention, or stroke or transient ischemic neurological disorder; Has a medical history of active liver disease, including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease; Has poorly controlled hypertension; Has severe peripheral vascular disease; Has human immunodeficiency virus (HIV); Has had a clinically important hematological disorder; Routinely consumes >2 alcoholic drinks per day or >14 alcoholic drinks per week, or engages in binge drinking; Has a history of intolerance or hypersensitivity or any contraindication to study medications (including sitagliptin, metformin, glimepiride, repaglinide, acarbose or gliclazide) based upon the Chinese label; Is on or likely to require treatment with ≥2 consecutive weeks or repeated courses of pharmacologic doses of corticosteroids (other than inhaled, nasal, or topical corticosteroids); Is pregnant or breast feeding or is expecting to conceive or donate eggs during the study, including 14 days following the last dose of study drug (female participants).
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Director
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
    IPD Sharing URL
    http://engagezone.msd.com/ds_documentation.php
    Citations:
    PubMed Identifier
    28271251
    Citation
    Xu W, Mu Y, Zhao J, Zhu D, Ji Q, Zhou Z, Yao B, Mao A, Engel SS, Zhao B, Bi Y, Zeng L, Ran X, Lu J, Ji L, Yang W, Jia W, Weng J. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial. Sci China Life Sci. 2017 Mar;60(3):225-238. doi: 10.1007/s11427-016-0409-7. Epub 2017 Feb 7.
    Results Reference
    result

    Learn more about this trial

    A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)

    We'll reach out to this number within 24 hrs